€100 Million Investment Round Prepares CureVac For Vaccine Expansion

03/11/2015 - 2 minutes

“The RNA People” at CureVac in Tübingen (Germany) have a new €100M investment into their RNA platform, which has prophylactic purposes for common viruses, pipeline candidates for prostate cancer, lung cancer and research into vaccines for HIV, Tuborculosis and Rabies.

logoIndeed, the financial success surrounding their mRNA work has been startlingly impressive, with the EU prize for Vaccines going to CureVac last year, and a hefty financial interest coming from the Bill & Melinda Gates Foundation (one round in March this year amounting to €46M).

In August it was announced that CureVac will also be collaborating with the Gates Foundation on a third development program using their mRNA platform for respiratory syncytial virus (RSV), which infects 64 million people each year.

Now, the latest €100M investment round was led by Scottish investment firm Baillie Gifford, and will be used to further expand its clinical programs in infectious diseases,

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
ADVERTISEMENT
Do you want to remove this advert? Become a member!
ADVERTISEMENT
Do you want to remove this advert? Become a member!

Support Us

Become a Member